Stocks · News reference
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from
8-K filing — Eledon Pharmaceuticals, Inc. (ELDN)
Filed: 2026-08-13 AccNo: 0001193125-26-349170 Size: 430 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in
Natera Announces Signatera Collaboration With Angiex To Develop A Portfolio Of Nuclear-Delivered Antibody-Drug Conjugates
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated